| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Human Endogenous Metabolite
8-Isoprostaglandin F2α is a weak thromboxane prostanoid (TP) receptor agonist in vascular smooth muscle. The compound targets the TP receptor, which is a G-protein coupled receptor that mediates the effects of thromboxane A2 and other prostanoids. Activation of the TP receptor leads to vasoconstriction, platelet aggregation, and smooth muscle proliferation. In addition to its TP receptor agonist activity, 8-isoprostaglandin F2α is also a biomarker of oxidative stress. It is produced by the nonenzymatic peroxidation of arachidonic acid in membrane phospholipids. As a biomarker, it reflects the extent of lipid peroxidation and oxidative damage in cells and tissues. The compound's role as a TP receptor agonist contributes to its vasoconstrictor effects, which may be involved in the pathophysiology of cardiovascular diseases. Its role as a biomarker makes it useful for diagnosing and monitoring oxidative stress-related diseases. |
|---|---|
| ln Vitro |
In vitro, 8-isoprostaglandin F2α exerts vasoconstrictor effects and induces a dose-dependent relaxation at lower doses after thromboxane A2 analog stimulation. The compound is used in cell-based assays to study its effects on vascular smooth muscle cells, endothelial cells, and other cell types. In these assays, cells are treated with 8-isoprostaglandin F2α at various concentrations (typically 0.1-10 μM), and cell contraction, proliferation, and signaling are assessed. The compound's effects on TP receptor signaling are measured by monitoring downstream pathways such as calcium mobilization, RhoA activation, and MAP kinase phosphorylation. The compound is also used in assays of oxidative stress to validate its role as a biomarker. In studies of inflammation, 8-isoprostaglandin F2α is used to assess the effects of oxidative stress on inflammatory responses.
|
| ln Vivo |
In vivo, infusion of 8-isoprostaglandin F2α induces renal vasoconstriction and decreases glomerular filtration rate (GFR). The compound's vasoconstrictor effects are mediated through TP receptor activation. In animal models, 8-isoprostaglandin F2α is used to study the pathophysiology of cardiovascular diseases, particularly those involving oxidative stress and vasoconstriction. The compound is also used as a biomarker in clinical studies to assess oxidative stress in patients with cardiovascular disease, diabetes, and other conditions. Levels of 8-isoprostaglandin F2α are measured in plasma, urine, and other biological fluids to assess the extent of lipid peroxidation. However, comprehensive in vivo pharmacokinetic studies have not been extensively reported. The compound is classified as a research chemical and is not approved for human use as a therapeutic agent.
|
| Enzyme Assay |
In vitro receptor binding assays for 8-isoprostaglandin F2α typically involve the use of the TP receptor. Membrane preparations from cells expressing the TP receptor are incubated with radiolabeled or fluorescently labeled thromboxane A2 or other TP receptor ligands in the presence of varying concentrations of 8-isoprostaglandin F2α. The binding affinity (IC₅₀ or Ki) is determined from competitive binding curves. For functional assays, cells expressing the TP receptor are treated with 8-isoprostaglandin F2α, and downstream signaling is measured. For example, calcium mobilization is measured using fluorescent calcium indicators, and RhoA activation is measured by pull-down assays. The compound's ability to act as an agonist is confirmed by measuring its ability to induce TP receptor-mediated signaling. Typical assay conditions include incubation at 25-37°C in appropriate buffer systems (pH 7.4), with reaction products measured by scintillation counting, fluorescence, or chemiluminescence.
|
| Cell Assay |
In vitro cell-based assays for 8-isoprostaglandin F2α are performed using vascular smooth muscle cells, endothelial cells, or other cell types that express the TP receptor. Cells are cultured in appropriate medium and treated with 8-isoprostaglandin F2α at various concentrations (typically 0.1-10 μM) for varying periods. Following treatment, cell contraction is assessed by measuring changes in cell area or by using collagen gel contraction assays. Cell proliferation is assessed using MTT or by counting cell numbers. Cell signaling is assessed by measuring calcium mobilization, RhoA activation, and MAP kinase phosphorylation. In studies of oxidative stress, cells are treated with 8-isoprostaglandin F2α, and markers of oxidative stress are measured. Each experiment includes appropriate controls (untreated cells, vehicle controls) and is performed in triplicate to ensure statistical reliability. The compound is typically dissolved in ethanol or DMSO as a stock solution and diluted in culture medium to the desired final concentration.
|
| Animal Protocol |
In vivo animal experiments with 8-isoprostaglandin F2α are conducted in mouse or rat models of cardiovascular disease, renal disease, or oxidative stress. Typically, 8-12 week old rodents are used, and the compound is administered via intravenous injection or infusion at doses ranging from 0.1-10 μg/kg/min. In models of renal vasoconstriction, the compound is infused into the renal artery, and renal blood flow and GFR are measured. In models of oxidative stress, the compound is administered to induce or assess oxidative damage. Blood and tissue samples are collected to measure compound concentrations and biomarkers of oxidative stress. All animal procedures are conducted in accordance with institutional animal care and use committee guidelines, with appropriate sample sizes (typically n=6-10 per group) to ensure statistical power. The compound is formulated for administration using appropriate vehicles such as saline or ethanol/saline mixtures. Endpoints include renal blood flow, GFR, biomarkers of oxidative stress, and histopathological examination.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of 8-isoprostaglandin F2α are characteristic of a prostaglandin-like molecule. With a molecular weight of 354.48 g/mol and moderate lipophilicity, the compound is expected to have limited oral bioavailability. Following intravenous administration, the compound is rapidly distributed to tissues and metabolized through prostaglandin metabolic pathways, including oxidation and reduction. The compound is rapidly cleared from circulation, with a half-life of minutes to hours. The compound exists in two distinct forms in human plasma, the phospholipid esterified and free acid forms. As a biomarker, its levels reflect the extent of lipid peroxidation and oxidative damage. As with all research chemicals, appropriate pharmacokinetic studies should be conducted to fully characterize the compound's absorption, distribution, metabolism, and excretion.
|
| Toxicity/Toxicokinetics |
The toxicological profile of 8-isoprostaglandin F2α has not been extensively characterized in formal toxicology studies. As an endogenous isoprostane produced by the nonenzymatic peroxidation of arachidonic acid, the compound is naturally present in the body at low concentrations. The compound is a weak TP receptor agonist and can cause vasoconstriction at high concentrations. However, its role as a biomarker suggests that it is generally non-toxic at the concentrations at which it is measured. Comprehensive toxicology studies including acute, subchronic, and chronic toxicity assessments have not been reported. The compound is classified as a research chemical and is not approved for human use as a therapeutic agent. Standard safety precautions should be observed when handling the compound, including the use of appropriate personal protective equipment.
|
| Additional Infomation |
8-Epicosprostaglandin F2α is an isoprostaglandin, a prostaglandin F2α with inverted stereochemistry at the 8-position. It functions as a bronchodilator, vasoconstrictor, and biomarker. Its function is related to prostaglandin F2α. It is the conjugate acid of 8-epicosprostaglandin F2α(1-). 8-Isoprostaglandin F2α is a biomarker for lipid peroxidation diseases and can be detected in serum, body fluids, and cell cultures using an ELISA immunoassay kit. Levels of 8-isoprostaglandin F2α are elevated in patients with non-insulin-dependent diabetes mellitus, coronary artery disease, and hypertension.
8-Isoprostaglandin F2α is a valuable research tool for studying oxidative stress, cardiovascular disease, and prostaglandin signaling. It is an isoprostane produced by the nonenzymatic peroxidation of arachidonic acid in membrane phospholipids. The compound is a major metabolite of PGF2α and is used as a biomarker for the diagnosis and treatment of cardiovascular-related diseases as well as a biomarker of total body oxidative stress. It has the molecular formula C₂₀H₃₄O₅ and a molecular weight of 354.48 g/mol. 8-Isoprostaglandin F2α is a weak TP receptor agonist in vascular smooth muscle. The compound exists in two distinct forms in human plasma, the phospholipid esterified and free acid forms. It is not approved for any clinical indication and is strictly for research use only. Its role as a biomarker of oxidative stress makes it an important tool for studying cardiovascular disease, inflammation, and oxidative stress. |
| Molecular Formula |
C20H34O5
|
|---|---|
| Molecular Weight |
354.48
|
| Exact Mass |
354.24
|
| CAS # |
27415-26-5
|
| PubChem CID |
5282263
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
531.0±50.0 °C at 760 mmHg
|
| Flash Point |
289.0±26.6 °C
|
| Vapour Pressure |
0.0±3.2 mmHg at 25°C
|
| Index of Refraction |
1.569
|
| LogP |
2.14
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
25
|
| Complexity |
432
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@H]1C/C=C\CCCC(=O)O)O)O)O
|
| InChi Key |
PXGPLTODNUVGFL-NAPLMKITSA-N
|
| InChi Code |
InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16-,17+,18-,19+/m0/s1
|
| Chemical Name |
(Z)-7-[(1S,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8210 mL | 14.1052 mL | 28.2103 mL | |
| 5 mM | 0.5642 mL | 2.8210 mL | 5.6421 mL | |
| 10 mM | 0.2821 mL | 1.4105 mL | 2.8210 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
